Skip to main content

REVIEW article

Oncol.Rev.
Sec. Oncology Reviews: Reviews
Volume 18 - 2024 | doi: 10.3389/or.2024.1427497

Novel -and not so Novel -Inhibitors of the Multifunctional CRM1 Protein

Provisionally accepted
Waitman Aumann Waitman Aumann 1,2*Rafi Kazi Rafi Kazi 3Amanda M. Harrington Amanda M. Harrington 4Daniel Wechsler Daniel Wechsler 1,2
  • 1 Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, United States
  • 2 Department of Pediatrics, Division of Pediatric Hematology/Oncology, Emory University, Atlanta, United States
  • 3 Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Rochester Medical Center, Rochester, NY, Rochester, Massachusetts, United States
  • 4 Department of Pediatrics, College of Medicine, University of Kentucky, Lexington, Kentucky, United States

The final, formatted version of the article will be published soon.

    Chromosome Region Maintenance 1 (CRM1), also known as Exportin 1 (XPO1), is a protein that is critical for transport of proteins and RNA to the cytoplasm through the nuclear pore complex.CRM1 inhibition with small molecule inhibitors is currently being studied in many cancers, including leukemias, solid organ malignancies and brain tumors. We review the structure of CRM1, its role in nuclear export, the current availability of CRM1 inhibitors, and the role of CRM1 in a number of distinct cellular processes. A deeper understanding of how CRM1 functions in nuclear export as well as other cellular processes may allow for the development of additional novel CRM1 inhibitors.

    Keywords: CRM1, XPO1, Cancer, Nuclear export, Leptomycin B

    Received: 03 May 2024; Accepted: 16 Jul 2024.

    Copyright: © 2024 Aumann, Kazi, Harrington and Wechsler. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Waitman Aumann, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.